Siwen Hu‐Lieskovan

Author

Siwen Hu‐Lieskovan

University of California, Los Angeles ORCID

Also Known As

Hu-Lieskovan, Siwen, S Hu-Lieskovan, S. Hu-Lieskovan, Siwen Hu-Lieskovan, Siwen Hu‐Lieskovan, Sophia Hu-Lieskovan

292

Publications

24.3K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles The University of Texas MD Anderson Cancer Center Huntsman Cancer Institute University of Utah UCLA Jonsson Comprehensive Cancer Center

About

Siwen Hu‐Lieskovan is an author at University of California, Los Angeles specializing in medicine, immunotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	16	2K
2	Immunology	12	12	677
3	Health Sciences	2	2	68
4	Cell Biology	2	2	106
5	Cellular Therapies	1	1	90

Siwen Hu‐Lieskovan

Publications

12.7K

Citations

H-Index

Page 1

	Year	Citations
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, New England Journal of Medicine	2016	3.1K
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno, Cell Reports	2017	1.8K
Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas, Cancer Discovery	2016	1.2K
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma Sapna P. Patel, Megan Othus, Yuanbin Chen, New England Journal of Medicine	2023	741
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer Patrick A. Ott, Siwen Hu‐Lieskovan, Bartosz Chmielowski, Cell UrologyMedicinePhase Ib TrialImmune Checkpoint InhibitorCancer Treatment	2020	699
Sequence-Specific Knockdown of EWS-FLI1 by Targeted, Nonviral Delivery of Small Interfering RNA Inhibits Tumor Growth in a Murine Model of Metastatic Ewing's Sarcoma Siwen Hu‐Lieskovan, Jeremy D. Heidel, Derek W. Bartlett, Cancer Research	2005	562
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> <sup> <i>V600E</i> </sup> melanoma Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno, Science Translational Medicine	2015	562
Genetic Mechanisms of Immune Evasion in Colorectal Cancer Catherine S. Grasso, Marios Giannakis, Daniel K. Wells, Cancer Discovery	2018	534
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster, Clinical Cancer Research	2018	347
High response rate to PD-1 blockade in desmoplastic melanomas Zeynep Eroglu, Jesse M. Zaretsky, Siwen Hu‐Lieskovan, Nature MelanomaHigh Response RateImmune Checkpoint InhibitorDermatologyImmunotherapy	2018	326

Page 1